December 16, 2025 — Leads & Copy — Stoke Therapeutics, Inc. (Nasdaq: STOK) announced that, effective December 15, 2025, it granted stock options to purchase 131,280 shares of common stock to eleven new employees as a material inducement to their employment. The stock options have an exercise price of $32.98 per share and will vest over a 4-year period. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
Stoke Therapeutics is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Stoke is headquartered in Bedford, Massachusetts.
Source: Stoke Therapeutics, Inc.
